Scholarlink

<p>Human endogenous retroviruses (HERVs), constituting roughly 8% of the human genome, have undergone a profound conceptual evolution from dismissed genomic “fossils” to critical, dualistic regulators in cancer biology. Their pathognomonic reactivation across malignancies orchestrates tumorigenesis through three interconnected molecular axes: (1) genomic destabilization via LTR-mediated insertional mutagenesis, disrupting key loci such as <i>TP53</i> and <i>MYC</i>; (2) immune checkpoint subversion, driven by HERV-K envelope glycoprotein-induced PD-L1 upregulation (2.3-fold; <i>p</i> &lt; 0.01); and (3) chronic inflammatory signaling triggered by double-stranded RNA (dsRNA) activation of innate immune pathways (TLR3/MDA5/NLRP3). This foundational mechanistic insight is accelerating clinical translation. Diagnostic advances now feature HERV-K Env-targeted liquid biopsies achieving 92% specificity (AUC = 0.94) for early-stage tumors and artificial intelligence (AI)-enhanced platforms (e.g., DeepHERV, AUC = 0.91) that resolve complex HERV expression landscapes. Therapeutically, an emerging pipeline of strategies is rapidly advancing, from initial first-in-human clinical trials (NCT05687903, NCT05554866) of HERV-directed monoclonal antibodies and vaccines to the highly promising preclinical efficacy demonstrated by HERV-K-specific chimeric antigen receptor (CAR) T-cells (&gt; 70% tumor regression) and locus-precise CRISPR/Cas9 epigenetic silencing. However, clinical translation is complicated by persistent challenges, including intratumoral HERV heterogeneity, a lack of assay standardization (as evidenced by 60% primer discordance), and the fundamental ethical and therapeutic requirement for specificity—that is, precise discrimination between pathogenic HERVs and their essential physiological counterparts. A convergent translational framework—leveraging international consortia for biomarker validation, machine learning for patient stratification, and engineered tumor-selective delivery platforms—is now positioned to harness this novel target class and redefine the next era of precision oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanisms biomarkers and therapeutic strategies of human endogenous retroviruses in cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Alfred Ndjekadom,
  • Yingying Bao,
  • Lichen Mao,
  • Liying Zhou,
  • Wenhui Shi,
  • Chenglin Zhou,
  • Wang Li,
  • Juan Xu,
  • Xiaochun Wang,
  • Yuwei Liu,
  • Shixing Yang,
  • Likai Ji,
  • Tongling Shan,
  • Hongfeng Yang,
  • Wen Zhang,
  • Quan Shen

摘要

Human endogenous retroviruses (HERVs), constituting roughly 8% of the human genome, have undergone a profound conceptual evolution from dismissed genomic “fossils” to critical, dualistic regulators in cancer biology. Their pathognomonic reactivation across malignancies orchestrates tumorigenesis through three interconnected molecular axes: (1) genomic destabilization via LTR-mediated insertional mutagenesis, disrupting key loci such as TP53 and MYC; (2) immune checkpoint subversion, driven by HERV-K envelope glycoprotein-induced PD-L1 upregulation (2.3-fold; p < 0.01); and (3) chronic inflammatory signaling triggered by double-stranded RNA (dsRNA) activation of innate immune pathways (TLR3/MDA5/NLRP3). This foundational mechanistic insight is accelerating clinical translation. Diagnostic advances now feature HERV-K Env-targeted liquid biopsies achieving 92% specificity (AUC = 0.94) for early-stage tumors and artificial intelligence (AI)-enhanced platforms (e.g., DeepHERV, AUC = 0.91) that resolve complex HERV expression landscapes. Therapeutically, an emerging pipeline of strategies is rapidly advancing, from initial first-in-human clinical trials (NCT05687903, NCT05554866) of HERV-directed monoclonal antibodies and vaccines to the highly promising preclinical efficacy demonstrated by HERV-K-specific chimeric antigen receptor (CAR) T-cells (> 70% tumor regression) and locus-precise CRISPR/Cas9 epigenetic silencing. However, clinical translation is complicated by persistent challenges, including intratumoral HERV heterogeneity, a lack of assay standardization (as evidenced by 60% primer discordance), and the fundamental ethical and therapeutic requirement for specificity—that is, precise discrimination between pathogenic HERVs and their essential physiological counterparts. A convergent translational framework—leveraging international consortia for biomarker validation, machine learning for patient stratification, and engineered tumor-selective delivery platforms—is now positioned to harness this novel target class and redefine the next era of precision oncology.